Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
Johnson & Johnson posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations ...
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback